ArticleTherapeutics and clinical risk management2024
Predicting Bleeding Related Events in Robotic-Assisted Partial Nephrectomy for Angiomyolipoma: Simplifying Risk Assessment with Tumor Diameter and Depth, A Retrospective Study.
Article in Therapeutics and clinical risk management, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemorrhage in Robot-assisted Partial Nephrectomy: A Multicentric, Retrospective Analysis of Blood Transfusion and Bleeding Requiring Intervention in 3726 Cases.European urology open science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evaluating risk factors for bleeding events in robot-assisted partial nephrectomy (RAPN) for renal angiomyolipoma (RAML) is essential for improving surgical outcomes. Methods: We performed a retrospective analysis of patients who underwent RAPN for renal masses between May 2019 and June 2023 at a single medical center, categorizing them into AML and non-AML groups. We assessed demographic data, perioperative complications, and postoperative outcomes. Preoperative imaging was reviewed to calculate R.E.N.A.L and PADUA nephrometry scores. Receiver operating characteristic (ROC) curve analysis was used to evaluate the accuracy of risk factors related to estimated blood loss (EBL) and blood transfusion. Results: Among 255 patients, 71 (27.8%) had AML, and 184 (72.2%) had non-AML. The average age was 54.5 years, with 80.2% of the AML group being female. The median tumor size was 50.2 mm. The AML group had larger tumor diameters (50.2 mm vs 34.9 mm) but shallower depths (16.1 mm vs 21.7 mm). Median R.E.N.A.L and PADUA scores were 6.5 and 8.2, respectively, with a median EBL of 128.2 mL. Blood transfusion was required in 15.5% of cases. Tumor diameter, depth, R.E.N.A.L score, and PADUA score significantly correlated with EBL, while BMI, tumor diameter, and R.E.N.A.L score correlated with blood transfusion. The AUCs for predicting EBL and blood transfusion were 0.778 and 0.771 for tumor diameter, and 0.661 and 0.711 for R.E.N.A.L score. Conclusion: RAPN might be a safe option for RAML, with tumor diameter being the most accurate predictor of EBL and blood transfusion. These findings can improve preoperative assessments and surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.